The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
Janssen Pharmaceutical’s (J&J) psoriasis therapy Stelara (ustekinumab) is facing a price slash of a whopping 40.8% in the FY2025 drug price revision, hit by the return of the price maintenance premium (PMP), Jiho has learned. MSD’s DPP-4 inhibitor Januvia (sitagliptin)…
To read the full story
Related Article
- Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
- J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
- MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
- Deferred PMP Cuts Likely to Batter Stelara; 7 Drugs Subject to Rule after LOE
December 24, 2024
REGULATORY
- AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026
- Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
- Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
- Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
- Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…